Drug Profile


Alternative Names: LUZ-11

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bluepharma; Universidade de Coimbra
  • Developer Luzitin
  • Class Antineoplastics; Macrocyclic compounds; Porphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 02 Jun 2017 Adverse events, efficacy and pharmacokinetics data from a phase II trial in Head and neck cancer presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 15 Mar 2016 Phase-II clinical trials in Head and neck cancer (Late stage disease) in Portugal (IV)
  • 20 Feb 2014 Phase-I/II clinical trials in Head and neck cancer in Portugal (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top